EFFICACY AND TOLERABILITY OF CANCER NEUROIMMUNOTHERAPY WITH SUBCUTANEOUS LOW-DOSE INTERLEUKIN-2 AND THE PINEAL HORMONE MELATONIN - A PROGRESS REPORT OF 200 PATIENTS WITH ADVANCED SOLID NEOPLASMS
- P LISSONI
- A ARDIZZOIA
- S BARNI
- F BRIVIO
- E TISI
- F ROVELLI
- G TANCINI
- G MAESTRONI
- L FUMAGALLI
Affiliations: OSPED SAN GERARDO,DIV SURG,I-20052 MONZA,ITALY. OSPED SAN GERARDO,DIV THORAC SURG,I-20052 MONZA,ITALY. INST PATHOL,LOCARNO,SWITZERLAND. KHIRON,MILAN,ITALY.
- Published online on: November 1, 1995 https://doi.org/10.3892/or.2.6.1063
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The recent advances in psychoneuroimmunology have demonstrated the existence of a psychoneuroendocrine control of the antitumor immunity. Our previous preliminary studies indicated the possibility of amplifying the biological and therapeutic efficacy of IL-2 cancer immunotherapy by immunomodulating neurohormones, mainly the pineal indole melatonin (MLT), in most advanced solid tumors, including those which generally do not respond to IL-2 alone. This study reports on the results obtained by low-dose IL-2 plus MLT in 200 patients with advanced solid neoplasms, for whom no other effective standard therapy was available. Non-small cell lung cancer, pancreatic adenocarcinoma, hepatocarcinoma, colon cancer and gastric cancer were the neoplasms most frequently detected in our patients. In addition, all patients had a life expectancy less than 6 months. IL-2 was given subcutaneously at 3 million IU/day for 6 days/week for 4 weeks; MLT was given orally at 40 mg/day. In non-progressing patients, a second cycle was given after a 21-day rest period; then, patients underwent a maintenance period consisting of one week of therapy every month until progression. A complete response (CR) was achieved in 4 patients (hepatocarcinoma 2; pancreas 1; gastric cancer 1), a partial reasponse (PR) was achieved in 36 patients (lung 12; liver 6; stomach 4; pancreas 3; colon 3; breast 2; miscellaneous 6). Tumor response rate (CR+PR) was 40/200 (20%) patients. Longer than one year survival was achieved in 79 (39%) patients. Toxicity was mild in all patients, and therapy was administered as a home therapy. The present study confirms in a great number of patients the possibility to induce objective tumor regressions in most advanced solid tumor histotypes by low-dose IL-2 plus MLT. Thus, immunotherapy with IL-2 and MLT may be considered as a new well tolerated and effective therapy of almost all advanced solid tumors, including those which do not respond to IL-2 alone or to chemotherapy.